.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AE02_Indinavir.Indinavir

Information

Indinavir is a protease inhibitor antiretroviral medication used in the treatment of HIV infection. It was previously widely used but has largely been replaced by newer agents due to adverse effects and resistance. It is still approved but rarely prescribed today.

Pharmacokinetics

Pharmacokinetics reported in healthy adult volunteers after oral administration.

References

1. Csajka, C, et al., & Buclin, T (2004). Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus. Antimicrobial agents and chemotherapy 48(9) 3226–3232. DOI:10.1128/AAC.48.9.3226-3232.2004 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15328077

2. Pfister, M, et al., & Sheiner, LB (2003). Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. Antimicrobial agents and chemotherapy 47(1) 130–137. DOI:10.1128/AAC.47.1.130-137.2003 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12499180

3. Zhou, XJ, et al., & Sommadossi, JP (2000). Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients. AIDS (London, England) 14(18) 2869–2876. DOI:10.1097/00002030-200012220-00008 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11153668

Revisions

• 06/2025 initial generated model